A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Trial Profile

A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Nutritional and metabolic diseases; Obesity
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 27 Apr 2017 Status changed from recruiting to completed.
    • 06 Apr 2017 Planned End Date changed from 31 Jul 2017 to 13 Apr 2017.
    • 06 Apr 2017 Planned primary completion date changed from 31 Jul 2017 to 13 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top